These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18715216)

  • 21. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
    Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
    Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
    Johansen NJ; Dejgaard TF; Lund A; Schlüntz C; Frandsen CS; Forman JL; Wewer Albrechtsen NJ; Holst JJ; Pedersen-Bjergaard U; Madsbad S; Vilsbøll T; Andersen HU; Knop FK
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):313-324. PubMed ID: 32135138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2018 Jan; 20(1):178-184. PubMed ID: 28722271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus.
    Liu M; Zhou Z; Yan J; Li P; Song W; Fu J; Chen X; Zhao W; Xi L; Luo X; Sha L; Deng X; Gong C
    BMC Endocr Disord; 2016 Nov; 16(1):67. PubMed ID: 27887605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus.
    Lin C; Cai X; Yang W; Lv F; Nie L; Ji L
    BMC Med; 2020 Nov; 18(1):322. PubMed ID: 33190640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes.
    Kovatchev B; Cobelli C
    Diabetes Care; 2016 Apr; 39(4):502-10. PubMed ID: 27208366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus.
    Kovatchev B; Umpierrez G; DiGenio A; Zhou R; Inzucchi SE
    J Diabetes Sci Technol; 2015 Jun; 9(6):1227-35. PubMed ID: 26078255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus.
    Lee NJ; Norris SL; Thakurta S
    Ann Fam Med; 2010; 8(6):542-9. PubMed ID: 21060125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoglycemia: from the laboratory to the clinic.
    Amiel SA
    Diabetes Care; 2009 Aug; 32(8):1364-71. PubMed ID: 19638523
    [No Abstract]   [Full Text] [Related]  

  • 32. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.
    Kovatchev BP; Crean J; McCall A
    Diabetes Technol Ther; 2008 Oct; 10(5):391-6. PubMed ID: 18715216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus.
    McCall AL; Cox DJ; Crean J; Gloster M; Kovatchev BP
    Diabetes Technol Ther; 2006 Dec; 8(6):644-53. PubMed ID: 17109596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
    Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
    Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.